Overview

Human Rabies Vaccines Market Overview:

Rabies is defined as a serious disease caused by the rabies virus. The rabies virus is a member of the Rhabodoviridae family and is generally found in animals. Humans are most likely to become infected by the bites of animals such as dogs, cats, bats, and other mammals. The rabies virus attacks the central nervous system, causing serious damage to the brain and, in extreme instances, death. Anxiety, paralysis, excessive salivation, hallucination, sleeplessness, hydrophobia, and other symptoms are common with rabies. As a result, rabies prophylaxis is critical, and vaccinations derived from inactivated rabies virus tend to greatly increase the worldwide human rabies vaccines market. Rabies is diagnosed in both animals and humans following the emergence of particular symptoms such as hydrophobia (fear of water) or aerophobia (fear of flying) (difficulty in respiration). These late-stage signs of infection can be lethal, hence an HRV should be delivered quickly after being bitten by rabid animals, even if these symptoms are not present. Human rabies vaccination can be given to people with the following forms of rabies:
Patients with livid rabies exhibit hyperactivity, hydrophobia, and aerophobia, and die after a few days owing to cardiopulmonary collapse. The course of paralytic rabies is longer than that of livid rabies. The muscle at the location of the wound becomes paralysed. Then, gradually, unconsciousness sets in, eventually leading to death. This kind is frequently misdiagnosed. It accounts for 30 percent of all human cases.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Human Rabies Vaccines Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Human Rabies Vaccines Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Human Rabies Vaccines Market:
• Serum Institute of India
• Sanofi Pasteur,Inc
• Novartis Vaccines and Diagnostics,Ltd
• Cadila Pharmaceuticals Ltd
• Merck and Co.Inc
• Glaxosmithkline Biologicals
• Berna Biotech Ltd
• Wyeth pharmaceuticals
• Medimmune LLC
• Cipla,Inc
(Note: The list of the major players will be updated with the latest market scenario and trends)

Human Rabies Vaccines Market Segmentation:
By Product Type
• Vero Cell Rabies Vaccine
• Baby Hamster Kidney (BHK)
• Chick Embryo Cell Rabies Vaccine
• Others

By Application
• Pre-Exposure Prophylaxis
• Post-Exposure Prophylaxis

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Human Rabies Vaccines Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Human Rabies Vaccines Market By Product Type, By Application and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1. Objectives of the Study
  1.2. Market Definition
  1.3. Market Scope
       1.3.1. Years Considered for the Study
       1.3.2. Market Covered
  1.4. Currency
  1.5. Limitations
  1.6. Stakeholders

2. Research Methodology
   2.1. Research Data
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation
   2.3. Market Breakdown and Data Triangulation
   2.4. Assumptions for the Study  

3. Executive Summary
  3.1. Market Outlook
  3.2. Segment Outlook
  3.3. Competitive Insights

4. Human Rabies Vaccines Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Type Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Human Rabies Vaccines Market Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Human Rabies Vaccines Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Type Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Type Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Human Rabies Vaccines Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Vero Cell Rabies Vaccine
  7.2. Baby Hamster Kidney (BHK)
  7.3. Chick Embryo Cell Rabies Vaccine
  7.4. Others

8. Human Rabies Vaccines Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
  8.1. Pre-Exposure Prophylaxis
  8.2. Post-Exposure Prophylaxis

9. North America Human Rabies Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
  9.1. Introduction
  9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       9.2.1. U.S.A
       9.2.2. Canada
       9.2.3. Mexico
  9.3. Market Size (USD Million) Forecast for North America 2022-2028

10. Latin America Human Rabies Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         10.2.1. Brazil
         10.2.2. Venezuela
         10.2.3. Argentina
         10.2.4. Rest of Latin America
   10.3. Market Size (USD Million) Forecast for Latin America 2022-2028

11. Europe Human Rabies Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         11.2.1. Germany
         11.2.2. U.K        
         11.2.3. France
         11.2.4. Italy
         11.2.5. Spain
         11.2.6. Russia
         11.2.7. Poland
         11.2.8. Rest of Europe
   11.3. Market Size (USD Million) Forecast for Europe 2022-2028

12. Asia Pacific Human Rabies Vaccines Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         12.2.1. Japan
         12.2.2. China
         12.2.3. India
         12.2.4. Australia and New Zealand
         12.2.5. ASEAN
         12.2.6. Rest of Asia Pacific
   12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

13. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         13.2.1. GCC
         13.2.2. Israel
         13.2.3. South Africa
         13.2.4. Rest of MEA
   13.3. Market Size (USD Million) Forecast for MEA 2022-2028

14. Market Share Analysis and Competitive Landscape  
   14.1. Global Landscape - Key Players, Revenue and Presence
   14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   14.3. Global Emerging Companies
   14.4. North America - Market Share Analysis and Key Regional Players
   14.5. Europe - Market Share Analysis and Key Regional Players
   14.6. Asia Pacific - Market Share Analysis and Key Regional Players
   14.7. Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   15.1. Serum Institute of India
         15.1.1. Company Overview
         15.1.2. Product Portfolio
         15.1.3. SWOT Analysis
         15.1.4. Financial Overview
         15.1.5. Strategic Overview
   15.2. Sanofi Pasteur,Inc
         15.2.1. Company Overview
         15.2.2. Product Portfolio
         15.2.3. SWOT Analysis
         15.2.4. Financial Overview
         15.2.5. Strategic Overview                        
   15.3. Novartis Vaccines and Diagnostics,Ltd
         15.3.1. Company Overview
         15.3.2. Product Portfolio
         15.3.3. SWOT Analysis
         15.3.4. Financial Overview
         15.3.5. Strategic Overview
   15.4. Cadila Pharmaceuticals Ltd
         15.4.1. Company Overview
         15.4.2. Product Portfolio
         15.4.3. SWOT Analysis
         15.4.4. Financial Overview
         15.4.5. Strategic Overview
   15.5. Merck and Co.Inc
         15.5.1. Company Overview
         15.5.2. Product Portfolio
         15.5.3. SWOT Analysis
         15.5.4. Financial Overview
         15.5.5. Strategic Overview          
   15.6. Glaxosmithkline Biologicals
         15.6.1. Company Overview
         15.6.2. Product Portfolio
         15.6.3. SWOT Analysis
         15.6.4. Financial Overview
         15.6.5. Strategic Overview      
   15.7. Berna Biotech Ltd
         15.7.1. Company Overview
         15.7.2. Product Portfolio
         15.7.3. SWOT Analysis
         15.7.4. Financial Overview
         15.7.5. Strategic Overview
   15.8. Wyeth pharmaceuticals
         15.8.1. Company Overview
         15.8.2. Product Portfolio
         15.8.3. SWOT Analysis
         15.8.4. Financial Overview
         15.8.5. Strategic Overview
   15.9. Medimmune LLC
         15.9.1. Company Overview
         15.9.2. Product Portfolio
         15.9.3. SWOT Analysis
         15.9.4. Financial Overview
         15.9.5. Strategic Overview
   15.10.Cipla,Inc        
         15.10.1. Company Overview
         15.10.2. Product Portfolio
         15.10.3. SWOT Analysis
         15.10.4. Financial Overview
         15.10.5. Strategic Overview
   15.11.Ferring Pharmaceuticals
         15.11.1. Company Overview
         15.11.2. Product Portfolio
         15.11.3. SWOT Analysis
         15.11.4. Financial Overview
         15.11.5. Strategic Overview
   15.12.Cipla Ltd
         15.12.1. Company Overview
         15.12.2. Product Portfolio
         15.12.3. SWOT Analysis
         15.12.4. Financial Overview
         15.12.5. Strategic Overview

16. Pre and Post COVID-19 Impact
   16.1. Positive influence on the healthcare industry
   16.2. The financial disruption of the manufacturing sector
   16.3. Impact of COVID-19 on emerging companies
   16.4. Significant mandates in the healthcare regulations initiated by administrations
   16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures